Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS.
Hong YS, Kim HJ, Park SJ, Kim KP, Lee JL, Park JH, Kim JH, Lim SB, Yu CS, Kim JC, Baek JY, Kim SY, Kim TW.
Hong YS, et al. Among authors: kim hj, kim tw, kim kp, kim sy, kim jc, kim jh.
Cancer Sci. 2013 Apr;104(4):473-80. doi: 10.1111/cas.12098. Epub 2013 Feb 14.
Cancer Sci. 2013.
PMID: 23298313
Free PMC article.